Logo for Dianthus Therapeutics Inc

Dianthus Therapeutics Investor Relations Material

Latest events

Logo for Dianthus Therapeutics Inc

M&A Announcement

Dianthus Therapeutics
Logo for Dianthus Therapeutics

Q2 2024

8 Aug, 2024
Logo for Dianthus Therapeutics

Q1 2024

9 May, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Dianthus Therapeutics Inc

Access all reports
Dianthus Therapeutics Inc., operating under the ticker DNTH, is a clinical-stage biotechnology company based in New York, New York. The company focuses on designing, developing, and delivering innovative monoclonal antibodies intended for the treatment of severe autoimmune and inflammatory diseases. Their key developmental product is DNTH103, currently in clinical trials, targeted at conditions such as generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. The company is headquartered in New York, NY, and its shares are listed on the NASDAQ.